BACKGROUND: Uterine inflammatory processes trigger prolabor pathways and orchestrate on-time labor onset. Although essential for successful labor, inflammation needs to be regulated to avoid uncontrolled amplification and resolve postpartum. During labor, myometrial smooth muscle cells generate ATP mainly via anaerobic glycolysis, resulting in accumulation of lactate. Aside from its metabolic function, lactate has been shown to activate a G protein-coupled receptor, GPR81, reported to regulate inflammation. We therefore hypothesize that lactate produced during labor may act via GPR81 in the uterus to exert in a feedback manner antiinflammatory effects, to resolve or mitigate inflammation. OBJECTIVE: We sought to investigate the role of lactate produced during labor and its receptor, GPR81, in regulating inflammation in the uterus. STUDY DESIGN: We investigated the expression of GPR81 in the uterus and the pharmacological role of lactate acting via GPR81 during labor, using shRNA-GPR81 and GPR81
Introduction
The onset of uterine labor is the culmination of a gradual uterine activation wherein physiological inflammation induces a common prolabor pathway characterized by increased myometrial contractility, weakening of fetal membrane integrity, and cervical ripening. Pathological proinflammatory stimuli, as observed in numerous etiologies of preterm birth (PTB), can induce !1 of the components of this common pathway resulting in preterm labor and is sufficiently pronounced to induce fetal/neonatal damage as has often been reported 1, 2 ; PTB is a leading cause of neonatal mortality and morbidity worldwide. [3] [4] [5] During labor metabolic demand increases beyond tissue oxygenation capacity. 6 To sustain the vigorous contractions of the myometrium, glycogen and glucose are utilized by myometrial smooth muscle cells (mSMC) to produce ATP under relative anaerobic conditions, leading to the accumulation of intermediates of carbohydrate metabolites, including lactate. 7 This anaerobic glycolytic metabolic pathway is extremely active (high lactate/pyruvate ratio) in myometrium during labor. 8 Accordingly, blood lactate levels of laboring women increase considerably as a function of the duration of labor. 9 Lately, lactate has been demonstrated to activate a G protein-coupled receptor, GPR81 (also labeled HCA 1 ). 10 This suggests that lactate has unexpected signaling functions beyond its traditional metabolic role. Along these lines, a role for lactate in the regulation of inflammation has been reported wherein lactate-induced stimulation of GPR81 in leukocytes specifically inhibited the inflammasome, 11 an important proinflammatory system active during labor 12 ; correspondingly, a tocolytic function for lactate has been postulated. 13 We thus proceeded to study the role of lactate and GPR81 in the uterus during labor. Herein, we describe a novel role for lactate in regulating inflammation during labor via activation of GPR81 in the uterus.
Materials and Methods

Experimental design
This study was designed to address the pharmacological role of lactate via its cognate receptor GPR81 in the uterus during labor, with a particular focus on its potential contribution to the intrauterine Loss-of-function experiments were designed to acquire direct evidence of the effect of GPR81 in the uterus using GPR81
e/e and GPR81 knocked-down mice. Specifically, we investigated the expression of GPR81 in the uterus during pregnancy using antibody-based methods, namely immunohistochemistry and immunoblotting. The transcriptional induction of genes of key inflammatory mediators (eg, Il6, Ccl2, Pghs2; see Table 1 for primer sequences) in response to GPR81 stimulation (with lactate or the specific GPR81 agonist 3,5-dihydroxybenzoic acid [DHBA] ), and with the addition of the major proinflammatory stimulant interleukin (IL)-1b, was measured ex vivo in uterus explants, in vitro in isolated mSMC, and in vivo in pregnant mice in labor. This set of experiments was designed to assess the potential antiinflammatory effect of uterine GPR81 when stimulated with exogenous lactate and 3,5-DHBA, or endogenous lactate during labor. Awidely used lipopolysaccharide (LPS)-induced PTB model was utilized to investigate the therapeutic potential of GPR81 stimulation as a mean to decrease uterine inflammation and consequently prevent preterm labor and neonatal mortality.
Animals
Timed-pregnant CD-1 mice were obtained from Charles River Inc (Senneville, Montreal, Québec, Canada) at G11 and allowed to acclimatize for 2 days prior to experiments. Animals were used according to a protocol of the Animal Care Committee of Hospital SainteJustine along the principles of the Guide for the Care and Use of Experimental Animals of the Canadian Council on Animal Care. The animals were maintained on standard laboratory chow under a 12:12 light:dark cycle and allowed free access to chow and water. GPR81
e/e mice were obtained from Lexicon Pharmaceuticals (The Woodlands, TX). The gestational time of GPR81
e/e and wild-type (WT) mice was monitored every 2 hours.
Chemicals
Chemicals were purchased from the following manufacturers: rhIL-1b (no. 200-01B; PeproTech, Quebec, Canada), lactate (no. L1750; Sigma, Oakville, Ontario, Canada), b-estradiol (no. 2758; Sigma), 3,5-DHBA (no. 54965; Sigma), and LPS Escherichia coli strain 0111:B4 (no. L2360; Sigma).
Lentivirus production and intrauterine injection
We produced infectious lentivirus (LV) by transiently transfecting lentivector and packaging vectors into 293FT cells (Invitrogen, Thermo Fischer Scientific, Burlington, Ontario, Canada) as previously described. 14 We used 5 different small hairpin RNA sequences against Gpr81 (RMM4534-EG243270; Dharmacon, GE Healthcare Life Sciences, Lafayette, CO) (see Table 1 for sequences) and selected the most effective (Supplementary Figure 4, A) . In vivo infections were performed in pregnant mice at G13 with a single intrauterine injection. Briefly, pregnant mice were steadily anesthetized with an isoflurane mask. After body hair removal from the peritoneal area, a 1.5-cm long median incision was made with surgical scissors in the lower abdominal wall. In all, 50 mL of vehicle, LV.shGFP, or LV.shGPR81 was injected in the lower segment of both uterine horns (100 mL total) between 2 fetal membranes with care to not enter the amniotic cavity. The abdominal muscle layer was then sutured and the skin closed with clips. LV were allowed to infect the uterus for 72 hours.
LPS-induced PTB model
Timed-pregnant CD-1 mice were carefully randomized by generating computer-aided randomized numbers for total animals, which were subsequently assigned to the indicated treatment groups as explained earlier. 15 Mice were pretreated at G13 with an intrauterine injection of vehicle (n ¼ 16), LV.shGFP (n ¼ 12), or LV.shGPR81 (n ¼ 15) (described in the section above). At G16, these animals were anesthetized with isoflurane and received an intraperitoneal injection of E coliederived LPS (single dose of 10 mg in 100 mL of saline); space limitations precluded performing these experiments in GPR81 knockout mice, as these studies require a large number of colonies. In other experiments, mice received only the LPS injection without a prior LV intrauterine injection. In all, 100 mL of pH-balanced 3,5-DHBA (25 mg/kg/8 hours) (n ¼ 20) or vehicle (n ¼ 36) was injected into these animals subcutaneously (in the neck skin) 30 minutes before LPS or vehicle stimulation (to allow distribution of the drug to target tissues in a preclinical efficacy study). The LPSinduced PTB model used was selected on the basis of reported documentation. 16 For both experiments, deliveries were monitored hourly until term (>G19). During labor (as confirmed with vaginal bleeding and newborns in the nest), female adults were anesthetized and uterine fragments from their lower uterus (cervical side) were collected, snap-frozen in liquid nitrogen, and kept at e80 C for subsequent RNA purification. In some cases ( Figure 5 ), randomized mice (selected on the same basis described above) were allowed to fully deliver to assess neonatal mortality.
Intrauterine IL-1b-induced PTB model
Timed-pregnant CD-1 mice at G16 were steadily anesthetized with an isoflurane mask. After body hair removal from the peritoneal area, a 1.5-cm long median incision was made with surgical scissors in the lower abdominal wall. The lower 37 C with agitation (100 rpm) for 30 minutes. The homogenate (still containing undigested myometrium fragments) was then poured through a 100-mm cell strainer. The resulting filtered solution was centrifuged at 200g for 10 minutes; the pellet was resuspended in complete DMEM medium and plated in a T-25 dish. The remaining myometrium fragments were re-used in an enzymatic digestion and the whole digestion-centrifugation process was repeated a total of 5 times. The first 2 digestion results were discarded because they contained mostly fibroblasts. The 3 other smooth muscle cellecontaining dishes were subjected to a differential adhesion technique to selectively enrich for uterine myocytes. Briefly, 30-45 minutes after the cells were first plated, the medium was removed and dispensed in another T-25 culture dish to separate quickly adhering fibroblast from slowly adhering myocytes. Cells were further analyzed in immunohistochemistry to assess culture purity with the smooth muscle cell marker a-actin 
Cell culture
Primary murine mSMC or human mSMC (hTERT cell line) were cultured in DMEM growth medium supplemented with 10% serum, 50 U/ mL penicillin, and 50 mg/mL streptomycin. Cells were propagated in regular conditions (37 C, 5% carbon dioxide). For in vitro experiments, cells (serumstarved overnight) or freshly isolated uterine fragments from WTor GPR81
e/e mice were treated with 5 ng/mL IL-1b and/or 10 mmol/L lactate (pHbalanced) or 100 mmol/L 3,5-DHBA for 8 hours. Lactate and 3,5-DHBA were added 30 minutes prior to IL-1b stimulation. Cells and tissues were then collected in Ribozol (AMRESCO, Solon, OH) and stored at e80 C for mRNA extraction.
RNA extraction and real-time quantitative polymerase chain reaction
RNA from tissues (from ex vivo stimulation [described above] or collected during pregnancy) or cells was extracted according to manufacturer's protocol. The RNA concentration and integrity were measured with a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). RNA (500 ng) was used to synthesize cDNA using iScript Reverse Transcription SuperMix (Bio-Rad, Hercules, CA). Primers were designed using Original Research OBSTETRICS
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Primer Blast (National Center for Biotechnology Information) ( Table 2) . Quantitative gene expression analysis was performed on MXPro3000 (Stratagene) with SYBR Green Master Mix (Bio-Rad). Gene expression levels were normalized to 18S universal primer (Ambion Life Technology, Burlington, Ontario, Canada). Dissociation curves were also acquired to test primer specificity. Genes analyzed included: Il1b, Il4, Il6, Il8, Ccl2 (chemokine ligand 2), Ptghs2 (prostaglandin H synthetase 2 or COX-2), Oxtr (oxytocin receptor), Mmp9 (metalloproteinase 9), Crp (C-reactive protein), Gja1 (connexin 43), and Gpr81.
Semiquantitative polymerase chain reaction
hTERT myometrial cells were pretreated with LV.shGFP or 3 different forms of shRNA encoded in LV (LV.shGPR81A,B,C) for 72 hours to verify efficacy of the latter in knocking down GPR81. Total RNA was isolated with RNase TM mini kit (Qiagen, Germantown, MD). Real-time polymerase chain reaction (only used to verify efficacy of shRNA) was performed as described previously. 18 QuantumRNA universal 18S standard primers (Ambion) were used as internal standard references. LV.shGPR81B was used in vivo to effectively knock down GPR81. Note that all other measurements of mRNA were performed by quantitative polymerase chain reaction.
Western blotting
Proteins from homogenized myometrium fragments collected during pregnancy lysed in RIPA buffer containing protease inhibitors were quantified using Bradford method (Bio-Rad). A total of 50 mg of protein sample were loaded onto sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrotransferred onto PVDF membranes. After blocking, membranes were incubated with an antibody against GPR81 (#SAB1300790, Sigma-Aldrich, Oakville, Ontario, Canada) After washing, membranes were incubated for 1 hour with their respective secondary antibodies conjugated to HRP (Sigma). Enhanced chemiluminescence (GE Healthcare, Little Chalfont, United 
GPR81 expressed in uterus on myometrial smooth muscle cells
Representative images of cryosections of uterus from A, nonpregnant and B, pregnant mice in labor revealing immunoreactivity to GPR81 and a-actin. Secondary antibodies alone were used as negative control (Supplementary Figure 1A) . Images are representative of 3 experiments. DAPI (blue) was used to stain nuclei. Scale, 20 mm. 
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Kingdom) was used for detection using the ImageQuant LAS-500 (GE Healthcare).
Lactate quantification assay
Age-matched laboring pregnant mice at term or nonlaboring pregnant mice at term were sacrificed and their uteri were snap-frozen in liquid nitrogen and stored at e80 C for <1 month. A fragment of 400 mg of each uterus was homogenized and used to quantify tissue lactate concentration using a colorimetric assay following manufacturer's protocol (K627; BioVision, Milpitas, CA). Readings were made on a microplate reader (EnVision Multilabel reader; PerkinElmer, Waltham, MA) adjusted for 450 nm. A standard curve of nmol/well vs OD450 nm was plotted and sample readings were applied and calculated using C ¼ La/Sv (nmol/mL or mmol/L); where La ¼ lactic acid amount (nmol) of sample from standard curve, and Sv ¼ sample volume (mL) added into the well. Results were then converted into a concentration unit (mmol/L) using the above standard curve. Interassay variation (for standards) is 0.5 mmol/L (based on laboratory and manufacturer).
Immunohistochemistry mSMC were plated on coverslips precoated with poly-D-lysine and fixed in 4% paraformaldehyde. After blocking, cells were incubated overnight with rabbit anti-a-actin (no. ab5694; Abcam, Toronto, Ontario, Canada) and then for 1 hour at ambient temperature with a secondary antibody conjugated with Alexa Fluor 488 (green) (Thermo Fisher Scientific). For tissue immunohistochemistry, uteri from pregnant mice in labor and nonpregnant mice were cleansed of fat and vessels and fixed in 4% paraformaldehyde for 1 day and transferred in 30% sucrose for another day. Localization of GPR81 was determined on 14-mm uterine sagittal cryosections. Sections blocked with 1% bovine serum albumin, 1% goat serum, and 0.1% Triton X-100 (T-8787; Sigma) in PBS were subsequently incubated overnight with the primary antibodies. Secondary antibodies conjugated with Alexa Fluor (Thermo Fisher Scientific) directed against rabbit were incubated for 2 hours at ambient temperature. Nuclei were stained with DAPI (1/5000) (Invitrogen). Images were captured using Â10 (for whole uterus imaging) or Â30 (for cell and magnified uterus imaging) objective with Eclipse E800 fluorescence microscope (Nikon, Mississauga, Ontario, Canada). Whole uterine images were captured using an AxioObserver.Z1 (Zeiss, San Diego, CA). Images were merged into a single file using the MosiaX option in AxioVision software, Version 4.6.5 (Zeiss).
Statistical analysis
Groups were compared by 1-way analysis of variance. Dunnett multiple comparison method was employed when treatments were compared to a single control. A value of P < .05 was considered statistically significant. Data are presented as means AE SEM.
Results
The lactate receptor GPR81 is expressed in the uterus and its expression increases during pregnancy; lactate levels are highest during labor GPR81 was found in the uterus of pregnant mice in labor (G19) and nonpregnant mice within the myometrium layer ( Figure 1) ; no immunoreactivity to GPR81 was found in uteri 
from GPR81
e/e mice ( Supplementary  Figure 1) , demonstrating specificity; GPR81 was also localized intracellularly, as reported for many other GPCRs. 19, 20 mRNA expression of Gpr81 in the uterus increased at G14 (approximately 75% of normal murine gestation length) and remained high (compared to nonpregnant mice) until labor (albeit borderline significantly increased in term labor), after which it decreased at postpartum (Figure 2, A) . Concordantly, translated protein expression of GPR81 in the uterus was highest toward the end of gestation at G16 and remained so until parturition (Figure 2, B) . Consistently, uterine lactate concentration markedly increased during labor from 2 to 9 mmol/L (Figure 2, C) .
Lactate exerts antiinflammatory effects on uterine tissue and myometrial cells via GPR81
We investigated if lactate/GPR81 modulated inflammation in the uterus. Uterine explants (from nonpregnant mice) were stimulated with IL-1b, a major proinflammatory cytokine implicated in labor, 21, 22 with and without (pH-buffered) lactate (10 mmol/L; ). IL1b caused comparable induction of proinflammatory and prolabor genes in nonpregnant mouse uterus from WT and GPR81-null mice ( Figure 3 ). As expected, lactate significantly attenuated expression of the numerous IL-1b-induced proinflammatory and prolabor genes in uteri of WT animals, but was ineffective on uteri of GPR81-null mice (Figure 3) . Effects of lactate on proinflammatory genes were corroborated on primary mSMC (Supplementary Figure 2 for purity of cells) from WT and GPR81-null mice (Supplementary Figure 3, A) . Hence, lactate acting via GPR81 conveys antiinflammatory effects on myometrial cells.
GPR81 suppresses inflammation in the uterus in labor
We further explored the role of GPR81 on uterine inflammation of animals in labor (at start of pup expulsion). Increased expression of proinflammatory Il1b, Il6, Pghs2, Ccl2, Mmp9, and Crp, but not of antiinflammatory Il4 was detected in GPR81-null compared to WT mice (Figure 4, A) . To rule out possible attenuating compensatory mechanisms that can occur in germ-line gene knockout mice, we performed similar studies after knocking down GPR81 in the uterus using a lentiviral-encoded shRNA targeting Gpr81 (found to be effective in hTERT cells [used to select efficacious shRNA] [Supplementary Figure 4 , A], and confirmed in vivo [Supplementary Figure 4 , B]), which was injected intrauterine to WT mice in intact and in LPStreated animals ( Figure 4 , B and C). An increase in proinflammatory gene transcripts in the uterus during labor analogous to that observed in GPR81-null mice was detected in GPR81 knockeddown mice ( Figure 4, B) ; lentiviralencoded GFP exerted no effect. Since the increased uterine inflammation in GPR81-silenced mice occurs during labor process, gestation length was not affected (Supplementary Figure 4, C and E).
In addition to term labor, we studied the role of GPR81 in preterm labor 
Lactate modulates uterine inflammation via GPR81
Lactate acts via GPR81 to inhibit interleukin (IL)-1b-induced transcription of numerous proinflammatory genes. Quantitative polymerase chain reaction of A, proinflammatory and B, prolabor messenger RNA (mRNA) transcripts performed on ex vivo uteri from nonpregnant mice treated with IL-1b (5 ng/mL) or vehicle (Veh) with or without lactate (10 mmol/L) for 8 hours. Results are normalized with 18S and are relative to control. Values are presented as mean AE SEM. n ¼ 3. *P < .05; **P < .01; ***P < .001 by 1-way analysis of variance with Dunnett multiple comparison test compared to IL-1b.
ns, not significant; WT, wild type. Figure 3, B) . Altogether, data suggest that lactate/GPR81 suppresses inflammation during labor (term and preterm).
Selective stimulation of GPR81 attenuates inflammation and prevents LPS-induced PTB
Based on antiinflammatory properties of GPR81 in the uterus we proceeded to establish whether stimulation of GPR81 prevents PTB. For this purpose, we utilized a metabolically stable and selective agonist of GPR81, 3,5-DHBA, which is also more potent (EC 50 z 150 mmol/L) than metabolizable lactate (EC 50 z 5 mmol/L). 25 We first confirmed the antiinflammatory properties of (pHbuffered) 3,5-DHBA on IL-1b-induced transcripts of IL-6, PGHS2, and CCL2 on ex vivo uteri (Supplementary Figure 4,  F) ; 3,5-DHBA had no effects on GPR81-null uteri. Likewise, uterine inflammation in mice treated with LPS (at G16) was abrogated by (subcutaneous) 3,5-DHBA ( Figure 5, A) , which was also effective in prolonging gestation shortened by LPS ( Figure 5 
Comment
Principal findings of the study
Herein, we describe the glycolytic product lactate as a novel endogenous antiinflammatory signaling molecule in the uterus acting via GPR81, thus providing an unprecedented mechanistic link between metabolism and inflammation in reproductive tissue; a schematic diagram of this concept is presented in Figure 6 . In line with high concentrations of lactate generated during labor (w10 mmol/L), corresponding concentrations are shown to exert antiinflammatory effects via GPR81 in myometrium, and conversely in vivo silencing of GPR81 amplifies uterine inflammation during labor. Concordantly, selective stimulation of GPR81 attenuates inflammation induced by proinflammatory agents and in turn normalizes gestational length and neonatal survival.
Meaning of the findings
Uterine contractions that occur during labor are intense and associated with recurrent periods of hypoxia, leading to the accumulation of lactate from pyruvate during glycolysis. 26 Glucose is the main energy substrate of the human myometrium during pregnancy, 8, 27 and expression of lactate dehydrogenases responsible for the conversion of lactate from pyruvate is found to increase near term in myometrium, inducing a shift Original Research OBSTETRICS ajog.org toward an anaerobic profile. [28] [29] [30] Of interest, anaerobic metabolism of glucose is significantly more active in myometrium than in striated muscles 8 known to generate lactate during exercise. Accordingly, lactate production is expected to rise abruptly during labor especially with sustained uterine contractions, 9,31 causing maternal (blood) and fetal (blood, amniotic fluids) lactate levels to increase in parturient women and animals and their progeny, 9, 32, 33 consistent with the murine data presented herein.
Once lactate is produced, its transport (into or out of the cellular compartment) is facilitated by monocarboxylate transporters. During anaerobic conditions outward flow of lactate dominates over intracellular transport in mSMC. 34 Hence during labor lactate flows out of the mSMC to bind to membrane-bound GPR81, at concentrations consistent with the affinity of GPR81 for lactate (w5 mmol/L) 10 ; the inherently low affinity of GPR81 for its ligand is consistent with other GPCRs of the same family, notably GPR109A and GPR109B. 35 High uterine lactate concentrations as observed during parturition are not likely to be achieved under other physiological circumstances, which may restrict the role of GPR81 to labor only. This claim is consistent with the amplified uterine inflammation observed in GPR81
e/e mice during labor, as well as in Gpr81 knocked-down mice in labor at term or at preterm (induced by inflammatory stimuli); whereas uteri from nonpregnant animals respond similarly to an inflammatory stimulus in WT and GPR81-null mice. Our data further suggest that GPR81 has a limited role during pregnancy before the onset of labor, as evidenced by unaffected gestational length in GPR81
e/e mice and in GPR81 knocked-down mice treated with LPS. Again, this is most likely due to insufficient local lactate concentrations during gestation in the quiescent uterus as well as during the inflammatory preparatory phase of the yet inactive uterus. In line, exogenous stimulation of GPR81 with a pharmacologic agonist can reduce inflammation and prevent PTB as observed with ; yet this does not apply to Gpr81, which is consistent with our hypothesis that GPR81 is specifically active during labor when lactate levels are increased. Altogether, our data suggest that lactate accumulates in the uterus during labor to act via GPR81 thereby regulating inflammation and restore tissue function (postpartum). The antiinflammatory action of lactate via GPR81 described herein is concordant with the recent finding that lactate/GPR81 inhibits 
Clinical implications
This work may convey clinical implication as it suggests that lactate is pharmacologically active in the uterus and that high concentrations of lactate regulate inflammation during labor to restore normal tissue function thereafter. This is consistent with an early study by Quenby et al 37 suggesting that women with dysfunctional labor have lower hemoglobin saturation with O 2 and higher lactate levels in capillaries from the lower segment of the uterus. Accordingly, more recent studies have demonstrated that high (!5.0 mmol/L) amniotic fluid lactate levels accurately predict labor disorders. 38, 39 Although sustained reduction in oxygenation of the uterus during labor directly leads to impaired fetal oxygenation and lactate accumulation in amniotic fluids, whether amniotic fluid and myometrial levels of lactate correlate is not yet known. Nonetheless it is interesting to point out that these high lactate concentrations correspond to >EC 50 of GPR81 implying plausible activation of GPR81. In this context, lactate was suggested to exert tocolytics Labor-induced lactate modulates uterine inflammation via GPR81
Schematic representation of antiinflammatory action of lactate acting via GPR81 in uterus during labor. A, Schematic representation and B, representative image of murine pregnant uterus. C, Schematic representation of proposed mechanism of action of uterine lactate/GPR81 wherein anaerobic glycolysis, main generator of ATP in myometrium during labor, produces lactate that diffuses out of myometrial smooth muscle cells to activate its cognate receptor GPR81, thereby decreasing transcription of proinflammatory genes. D, Expression of GPR81, levels of lactate, and inflammatory profile in murine pregnant uterus during gestation and labor.
ATP, adenosine triphosphate; GPR, G protein-coupled receptor. Original Research OBSTETRICS ajog.org effects, 13 in addition to its desirable antiinflammatory effect reported herein. Pharmacological stimulation of GPR81 may provide benefits by directly attenuating excessive detrimental inflammation for the fetus/newborn.
Research implications
The onset of labor is an intricate phenomenon orchestrated by an acute/subacute uterine inflammatory response, 40, 41 particularly relevant in a high proportion of PTB, especially at 21-24 weeks where the rates are >94%. 42 In preparation for labor, the uterus is invaded by myeloid cells (eg, neutrophils, macrophages) that actively produce proinflammatory mediators (eg, cytokines, chemokines, prostaglandins) in the vicinity of decidual, chorionic, and myometrial cells. [43] [44] [45] Combined with specific hormonal changes (eg, progesterone withdrawal), these factors directly lead to induction of uterotonic proteins in gestational tissue, which is a prerequisite to the on-time onset of labor. 3 Although inflammation conveys critical functions before and during labor, inflammation needs to be controlled and tissue function must be restored postpartum.
Lactate/GPR81 plausibly partakes in the resolution of inflammation that occurs postpartum. Inflammation needs to be terminated to avoid negative maternal outcomes, such as postpartum endometritis. 46 The resolution of inflammation is an active process that involves the action of antiinflammatory and proresolution modulators such as lipoxins, resolvins, protectins, IL-10, and 15d-PDJ 2 . 47 The involvement and importance of this process in gestational tissues is still ill-defined. Recently, MaldonadoPerez et al 48 described lipoxin A 4 as a potential proresolution factor active after labor in both physiological and pathological human labor. This study revealed the antiinflammatory effects of lipoxin A 4 on ex vivo uterine biopsies, in addition to an increased expression of the lipoxin A 4 receptor FRP2 in laboring myometrium. Interestingly, our observations presented herein on lactate/ GPR81 in myometrium complement those related to other mediators.
Strengths and limitations
Strengths
This study provides converging in vitro, ex vivo, and in vivo evidence that lactate exhibits GPR81-mediated antiinflammatory effects in the uterus during labor. To our knowledge, this is the first study addressing the pharmacological role of an intermediate of carbohydrate metabolites in the pregnant uterus and therefore opens new areas of investigation that possibly expand beyond labor. Intermediates of carbohydrate metabolites accumulate under hypoxic conditions in the body 49 ; such a condition is observed in the uterus during physiological labor, as well as in pathological conditions (eg, preterm labor, cancer, primary dysmenorrhea, preeclampsia). 50, 51 Other than lactate, succinate and a-ketoglutarate are 2 citric acid cycle intermediates that accumulate during hypoxia and exhibit pharmacological activity via GPR91 and GPR99, respectively 52 ; notably angiogenic properties of GPR91 have been documented. 53 Therefore, intermediates of carbohydrate metabolites may represent a new mechanistic link between hypoxia and the pathophysiology of certain diseases of the female reproductive tract.
Limitations
Although mice and human beings share similarities in some physiological and mechanistic aspects of their gestation and parturition, differences exist particularly as they apply to endocrinology and immunology. 54, 55 Notwithstanding dissimilarities, GPR81 mRNA is found in the human uterus 56 and our data suggest that GPR81 stimulation of human mSMC exerts similar antiinflammatory effects as those observed in mice.
Conclusions
In summary, we report an antiinflammatory role of lactate via its receptor GPR81 in the uterus in labor. GPR81 expression increases as gestation nears the end, whereas lactate concentration considerably increases during labor. Lactate acts as an antiinflammatory signaling molecule on myometrium. These findings suggest a novel link between the anaerobic glycolysisethe main source of ATP during laboreand the control of uterine inflammation, whereby lactate augmented by vigorous uterine muscle contractions activates GPR81 to down-regulate transcription of key proinflammatory genes in the uterus, in what seems to be a feedback regulatory mechanism. n as loading control. B, shRNA-GPR81(B)-encoded LV injected in vivo was effectively used to knock down Gpr81 mRNA expression (quantitative PCR [qPCR]) in murine uterine tissue. C, Timing of birth monitored in wild-type (WT) and GPR81 e/e mice. D, Uterine expression of Gpr81 mRNA increases during preterm labor induced by intraperitoneal-injected lipopolysaccharide (LPS) at G16; LV.shGPR81 (at G13) suppresses this increase. 
